Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading ...

Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price down ...

If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.

Pfizer (PFE) remains in focus for income oriented investors, with recent returns ranging from a 2.1% decline over the past week to a 10.7% total return over the past year. See our latest analysis for ...

Pfizer beat on 2025 sales and beat on earnings -- but still delivered a loss. Pfizer reaffirmed 2026 sales and earnings guidance for under $3 per share. 10 stocks we like better than Pfizer › Pfizer ...

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance ...

Eli Lilly (NYSE: LLY) is growing very quickly right now thanks to Mounjaro and Zepbound, its two GLP-1 drugs, the latter of which is approved for weight loss. Mounjaro's sales ros ...